Department of Ultrasound, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Department of Head and Neck Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200001, China.
Endocrine. 2022 Aug;77(2):297-304. doi: 10.1007/s12020-022-03071-2. Epub 2022 May 19.
This study aimed to investigate the predictive factors as well as the time and age course of recurrence/persistence in a large cohort of postoperative patients with papillary thyroid carcinoma (PTC) based on the long-term ultrasonography (US) follow-up data.
Between January 2007 and December 2016, 3106 patients underwent surgery for PTC and at least two postoperative US follow-up examination over more than three years. Tumor recurrence/persistence was confirmed based on the follow-up US data and histopathological results. Univariate and multivariate analyses were performed to evaluate the predictive factors of tumor recurrence/persistence. Kaplan-Meier survival analysis was used to evaluate the recurrence-/persistence-free survival curve based on the US results.
A total of 321(10.3%) patients developed tumor recurrence/persistence during 54.3 months of mean follow-up (range 36-135 months), including 268(83.5%) cases of lymph node recurrence/persistence, 37 (11.5%) cases of non-lymph node recurrence/persistence, and 16(5%) cases of both types. Recurrence/persistence was observed using US examination at a mean interval of 23.6 ± 21.6 months (range 1-135 months) after surgery and peak incidence was observed 1-2 years after initial treatment. Younger (20-30 years old) and older (70-80 years old) patients had a higher proportion of tumor recurrence/persistence. Multifocality, advanced T and advanced N stages were independent risk factors of tumor recurrence/persistence.
Tumor recurrence/persistence of PTC usually occurs during the early postoperative period. For patients with multifocal cancer, advanced T and N stage, the US surveillance examination should be cautiously performed, especially in younger and older patients.
本研究旨在通过长期超声(US)随访数据,调查大量术后甲状腺乳头状癌(PTC)患者的复发/持续存在的预测因素以及时间和年龄进程。
2007 年 1 月至 2016 年 12 月,3106 例 PTC 患者接受手术治疗,且术后至少进行了两次超过三年的 US 随访检查。根据随访 US 数据和组织病理学结果,确认肿瘤复发/持续存在。进行单变量和多变量分析,以评估肿瘤复发/持续存在的预测因素。Kaplan-Meier 生存分析用于根据 US 结果评估复发/持续无病生存曲线。
在平均 54.3 个月的随访期间(范围 36-135 个月),共有 321 例(10.3%)患者发生肿瘤复发/持续存在,其中 268 例(83.5%)为淋巴结复发/持续存在,37 例(11.5%)为非淋巴结复发/持续存在,16 例(5%)为两种类型。在手术后 23.6±21.6 个月(范围 1-135 个月)平均间隔时间内通过 US 检查发现复发/持续存在,且发病高峰出现在初始治疗后 1-2 年。年轻(20-30 岁)和年长(70-80 岁)患者的肿瘤复发/持续存在比例更高。多发病灶、晚期 T 期和晚期 N 期是肿瘤复发/持续存在的独立危险因素。
PTC 的肿瘤复发/持续存在通常发生在术后早期。对于多灶性癌症、晚期 T 期和 N 期的患者,应谨慎进行 US 监测检查,尤其是在年轻和年长的患者中。